Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate
Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $2.39 million which beat the analyst consensus estimate of $2.01 million by 18.71 percent. This is a 54.44 percent decrease over sales of $5.24 million the same period last year.
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $2.39 million which beat the analyst consensus estimate of $2.01 million by 18.71 percent. This is a 54.44 percent decrease over sales of $5.24 million the same period last year.
Lineage Cell Therapeutics（AMEX: LCTX）公佈的季度每股虧損爲0.03美元。與去年同期相比，每股虧損0.04美元，增長了25％。該公司公佈的季度銷售額爲239萬美元，比分析師共識估計的201萬美元高出18.71％。這比去年同期的524萬美元銷售額下降了54.44％。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧